Navigation Links
AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008
Date:11/6/2008

.com" target="_new">http://www.amdl.com or contact AMDL's investor relations department at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 400 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(206) 310-5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
2. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
3. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires
4. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
5. AMDL, Inc. Announces Strategic Realignment
6. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
7. AMDL, Inc. Closes Private Placement of Convertible Notes
8. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
11. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... -- Naurex Inc., a biopharmaceutical company leveraging its unique ... central nervous system, today announced that Norbert Riedel ... at the 33 rd annual J.P. Morgan Healthcare ... p.m. PST on Tuesday, January 13, 2015, at the ... About Naurex Inc. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , ROCKVILLE, Md., Nov. 30 Novavax, Inc. (Nasdaq: NVAX ... be presenting at the 21st Annual Health Care Conference 2009 on ... York Palace, New York. Novavax will provide an overview of ... A link to the live audio only presentation can be ...
... , CHANGCHUN, China ... Inc. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharmaceuticals, or ,the ... Northeastern China, today announced it has,completed preparation for distribution ... The Chinese government recently formalized the ...
... ... (Nasdaq and MTA: CTIC) announced today that its new ... stronger anti-tumor potency and activity compared to currently available ... cisplatin-resistance in cancer cell lines. The results were ...
Cached Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... release is available in German . Plants, ... The early detection of pathogens and the subsequent immune response, ... shield. However, the pathogens that cause plant diseases have their ... wall reaction in plants. "One particularly ingenious attacker, powdery mildew, ...
... The scientific equivalent of searching for a needle in ... for potential new medicines for Parkinson,s Disease and other ... American Chemical Society,s award-winning " Global Challenges/Chemistry Solutions " ... 390,000 chemical compounds. Finally, they located one that blocks ...
... children to stop slouching for ages. It turns out ... only makes a bad impression, but can actually make you ... professor of management organization at the USC Marshall School of ... Rotman School of Management at the University of Toronto, adopting ...
Cached Biology News:TUM researchers discover a new switch in resistance to plant diseases 2Your mother was right: Study shows good posture makes you tougher 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: